Cargando…

COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services

The COVID-19 pandemic has increased the uptake of virtual and remote service delivery in the substance use field, which was previously uncommon. This swift uptake of virtual services provides an opportunity to improve service design to meet the diverse needs of women and gender-diverse people. Such...

Descripción completa

Detalles Bibliográficos
Autores principales: Perri, Melissa, Schmidt, Rose A., Guta, Adrian, Kaminski, Nat, Rudzinski, Katherine, Strike, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359504/
https://www.ncbi.nlm.nih.gov/pubmed/35969920
http://dx.doi.org/10.1016/j.drugpo.2022.103815
_version_ 1784764152827346944
author Perri, Melissa
Schmidt, Rose A.
Guta, Adrian
Kaminski, Nat
Rudzinski, Katherine
Strike, Carol
author_facet Perri, Melissa
Schmidt, Rose A.
Guta, Adrian
Kaminski, Nat
Rudzinski, Katherine
Strike, Carol
author_sort Perri, Melissa
collection PubMed
description The COVID-19 pandemic has increased the uptake of virtual and remote service delivery in the substance use field, which was previously uncommon. This swift uptake of virtual services provides an opportunity to improve service design to meet the diverse needs of women and gender-diverse people. Such services have the potential to better meet the needs of women and gender-diverse people by allowing for increased choice, control, and autonomy, enabling empowerment, facilitating greater considerations of power relations, violence, childcare responsibilities, and fostering greater inclusion of trans and non-binary people. This commentary aims to identify how virtual and remote delivery of substance use treatment and harm reduction services can be gender-responsive. We highlight the role gender transformative services play in meeting the unique needs of women and gender-diverse people who use drugs both during and after the COVID-19 pandemic. By using the unique window of opportunity COVID-19 has created to develop and deliver gender-transformative programs, we can help address the detrimental gaps in service accessibility and effectiveness that have persistently been experienced by women and gender-diverse people who use drugs.
format Online
Article
Text
id pubmed-9359504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-93595042022-08-09 COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services Perri, Melissa Schmidt, Rose A. Guta, Adrian Kaminski, Nat Rudzinski, Katherine Strike, Carol Int J Drug Policy Commentary The COVID-19 pandemic has increased the uptake of virtual and remote service delivery in the substance use field, which was previously uncommon. This swift uptake of virtual services provides an opportunity to improve service design to meet the diverse needs of women and gender-diverse people. Such services have the potential to better meet the needs of women and gender-diverse people by allowing for increased choice, control, and autonomy, enabling empowerment, facilitating greater considerations of power relations, violence, childcare responsibilities, and fostering greater inclusion of trans and non-binary people. This commentary aims to identify how virtual and remote delivery of substance use treatment and harm reduction services can be gender-responsive. We highlight the role gender transformative services play in meeting the unique needs of women and gender-diverse people who use drugs both during and after the COVID-19 pandemic. By using the unique window of opportunity COVID-19 has created to develop and deliver gender-transformative programs, we can help address the detrimental gaps in service accessibility and effectiveness that have persistently been experienced by women and gender-diverse people who use drugs. Elsevier B.V. 2022-10 2022-08-08 /pmc/articles/PMC9359504/ /pubmed/35969920 http://dx.doi.org/10.1016/j.drugpo.2022.103815 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Perri, Melissa
Schmidt, Rose A.
Guta, Adrian
Kaminski, Nat
Rudzinski, Katherine
Strike, Carol
COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
title COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
title_full COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
title_fullStr COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
title_full_unstemmed COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
title_short COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
title_sort covid-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359504/
https://www.ncbi.nlm.nih.gov/pubmed/35969920
http://dx.doi.org/10.1016/j.drugpo.2022.103815
work_keys_str_mv AT perrimelissa covid19andtheopportunityforgenderresponsivevirtualandremotesubstanceusetreatmentandharmreductionservices
AT schmidtrosea covid19andtheopportunityforgenderresponsivevirtualandremotesubstanceusetreatmentandharmreductionservices
AT gutaadrian covid19andtheopportunityforgenderresponsivevirtualandremotesubstanceusetreatmentandharmreductionservices
AT kaminskinat covid19andtheopportunityforgenderresponsivevirtualandremotesubstanceusetreatmentandharmreductionservices
AT rudzinskikatherine covid19andtheopportunityforgenderresponsivevirtualandremotesubstanceusetreatmentandharmreductionservices
AT strikecarol covid19andtheopportunityforgenderresponsivevirtualandremotesubstanceusetreatmentandharmreductionservices